Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Ascendiant Capital Maintains Buy on Daxor, Raises Price Target to $24.75

Author: Benzinga Newsdesk | September 09, 2024 05:57am
Ascendiant Capital analyst Edward Woo maintains Daxor (NASDAQ:DXR) with a Buy and raises the price target from $24.5 to $24.75.

Posted In: DXR

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist